Literature DB >> 12061215

[Non-toxic multinodular goitre: which surgery?].

G Scerrino1, G Salamone, M A Farulla, G Romano, S Salamone, G Pompei, G Buscemi.   

Abstract

AIM OF THE STUDY: Evaluation of total thyroidectomy, subtotal thyroidectomy and lobectomy in the management of multinodular non-toxic goitre.
MATERIALS AND METHODS: 225 patients: 101 total thyroidectomies, 64 sub-total thyroidectomies, 29 lobo-hystmectomies. Hemorrages, recurrent nerve palsies, post-operatory hypocalcemias, clinical and ultrasonographic relapses, undesired effects of ormonal therapy and hypothyroidism after partial resection (considered risk factor for recurrence) have been pointed out.
RESULTS: All three procedures showed a low incidence of recurrent nerve palsy; lobectomy didn't show post-operatory hypocalcemia, that appeared respectively in 26.6% and 23% after sub-total and total thyroidectomy. Recurrence's percentage in patients followed-up, was 18.2% after lobectomy and 12.2% after sub-total thyroidectomy, but in that group we observed 46.9% of hypothyroidism (vs. 9.1% after lobectomy) and 8.6% of undesired effects of therapy. Reoperations showed inferior laringeal palsy and post-operatory hypocalcemia significantly more elevated. DISCUSSION: Compared to lobectomy, total thyroidectomy showed higher risk of hypoparathyroidism; compared to subtotal thyroidectomy, it showed on all occasions less incidence of complications. Endocrinological follow-up is easier after total thyroidectomy.
CONCLUSIONS: According to our results, we deem the indications for lobectomy have to be limited to the patients having solitary nodule, undoubtedly benign, without familiarity or other environmental risk factor of goitre.

Entities:  

Mesh:

Year:  2001        PMID: 12061215

Source DB:  PubMed          Journal:  Ann Ital Chir        ISSN: 0003-469X            Impact factor:   0.766


  7 in total

Review 1.  Complications after reoperative thyroid surgery: retrospective evaluation of 152 consecutive cases.

Authors:  Fabio Medas; Massimiliano Tuveri; Gian Luigi Canu; Ernico Erdas; Pietro Giorgio Calò
Journal:  Updates Surg       Date:  2019-04-01

2.  The coexistence of primary hyperparathyroidism and thyroid nodules: should the preoperative work-up of the parathyroid and the thyroid diseases be specifically adjusted?

Authors:  G Scerrino; M Attard; C Lo Piccolo; A Attard; G I Melfa; C Raspanti; M Zarcone; S Bonventre; S Mazzola; G Gulotta
Journal:  G Chir       Date:  2016 May-Jun

3.  Impact of surgical technique on operative morbidity and its socioeconomic benefit in thyroid surgery.

Authors:  Anita Kurmann; Forian Martens; Roman Inglin; Stefan W Schmid; Daniel Candinas; Christian A Seiler
Journal:  Langenbecks Arch Surg       Date:  2012-07-18       Impact factor: 3.445

4.  Long-term esophageal motility changes after thyroidectomy: associations with aerodigestive disorders.

Authors:  G Scerrino; A Inviati; S Di Giovanni; N C Paladino; S Di Giovanni; N C Paladino; V Di Paola; C Raspanti; G I Melfa; F Cupido; S Mazzola; C Porrello; S Bonventre; G Gullotta
Journal:  G Chir       Date:  2017 Sep-Oct

5.  The prevalence of post-thyroidectomy chronic asthenia: a prospective cohort study.

Authors:  Gregorio Scerrino; Giuseppina Melfa; Cristina Raspanti; Andrea Attard; Sergio Mazzola; Roberto Gullo; Sebastiano Bonventre; Marco Attard; Gianfranco Cocorullo; Gaspare Gulotta
Journal:  Langenbecks Arch Surg       Date:  2017-03-15       Impact factor: 3.445

Review 6.  Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter? An evidence-based review.

Authors:  Gaurav Agarwal; Vivek Aggarwal
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

7.  Risk Factors for Anaplastic Thyroid Carcinoma: A Case Series From a Tertiary Referral Center for Thyroid Surgery and Literature Analysis.

Authors:  Giuseppa Graceffa; Giuseppe Salamone; Silvia Contino; Federica Saputo; Alessandro Corigliano; Giuseppina Melfa; Maria Pia Proclamà; Pierina Richiusa; Sergio Mazzola; Roberta Tutino; Giuseppina Orlando; Gregorio Scerrino
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.